Assistant Controller

Reporting to the VP Finance, this individual will play a critical role in assisting with the day-to-day accounting of a fast-paced biotech company.  The Assistant Controller will have the ability to work independently, as well as lead a team. This position is ideal for an individual who is interested in developing skills across a wide range of accounting functions and has a strong sense of urgency. The successful candidate will have a strong background in accounting and finance and the ability to work collaboratively with cross-functional teams possessing a “can do” attitude and a willingness to roll up their sleeves to ensure timely and accurate delivery of the work product required from the Accounting function.

Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts, with additional staff functioning in a virtual-based environment from the Greater Boston area and throughout the United States.

Major Duties / Responsibilities

Financial Management & Reporting

• Review and support the clinical accrual process
• Review the quarterly consolidation and financial statement workbook for SEC reporting
• Review the monthly / quarterly journal entries and reconciliations
• Own equity compensation systems, accounting and filings
• Assist with technical accounting research as needed
• Lead accounting system implementations as needed
• Supporting financial reporting for board meetings

Accounting Operations

Cross-Functional Collaboration

Education & Professional Experience

Required :

Working Conditions : Busy office / laboratory environment with frequent deadlines and interruptions

Travel : Travel is not required

Physical Requirements : Subject to periods of sitting or standing, vision is required to monitor data.

Work Location : This role can be hybrid or remote (occasional onsite presence is required)

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq : ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer immunotherapy ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com .

About the Amphiphile Platform

Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.